Experimental therapeutics for patients with myeloproliferative neoplasias (Q37797983)

23 August 2017

Experimental therapeutics for patients with myeloproliferative neoplasias (English)

1 reference

23 August 2017

4

Hagop Kantarjian

1 reference

23 August 2017

5

Srdan Verstovsek

1 reference

23 August 2017

3

Jorge Cortes

1 reference

PubMed ID

20922795

23 August 2017

Alfonso Quintas-Cardama

series ordinal

6

object named as

Alfonso Quintas-Cardama

1 reference

23 August 2017

2

Ravin J Garg

1 reference

23 August 2017

1

Meetu Agrawal

1 reference

PubMed ID

20922795

23 August 2017

language of work or name

English

0 references

publication date

4 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

117

1 reference

23 August 2017

4

1 reference

23 August 2017

662-676

1 reference

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

23 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Identification of an acquired JAK2 mutation in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

The myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Genetic complexity of myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Jak2 is essential for signaling through a variety of cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

A road map for those who don't know JAK-STAT

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

The haematocrit and platelet target in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Vascular complications in Chuvash polycythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Choosing between stem cell therapy and drugs in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

21 January 2018

The Janus kinases (Jaks)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

Myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

7 January 2021

Myelofibrosis. Clinical, hematologic and pathologic study of 110 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

7 January 2021

A clinical and pathological study of seventy cases of myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

7 January 2021

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

7 January 2021

Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

7 January 2021

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

7 January 2021

Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

7 January 2021

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

7 January 2021

Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

7 January 2021

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

7 January 2021

Thalidomide therapy for myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25672

7 January 2021

Identifiers

DOI

10.1002/CNCR.25672

1 reference

23 August 2017

1 reference

PubMed ID

20922795